Posted in | News | Nanobusiness

OCSiAI Acquires Zyvex Technologies to Form a New Nanotechnology Company

OCSiAl, the leading technology manufacturer for the mass industrial production of graphene tubes, announced today at a press conference at the TechConnect World Innovation Conference that it has acquired Zyvex Technologies, making the combined venture the largest nanotechnology company in the world.

The unprecedented partnership between OCSiAl and Zyvex Technologies will combine large scale manufacturing capabilities with commercialization expertise – unleashing limitless potential for enhanced consumer products across the globe.

OCSiAl is known for developing the world’s largest low cost and scalable production of graphene tubes under the brand name TUBALL®, while Zyvex Technologies is the acknowledged leader in the field of carbon nanomaterial applications. The latter’s nanotechnology-based products are already integrated into a diverse number of products, ranging from Easton sporting goods to Airbus next generation materials research. This acquisition will enable the mass availability of TUBALL® graphene tubes and provide endless advantages to customers across industries.

“From improved quality and durability of consumer goods to premier, high level projects, the combination of OCSiAl’s manufacturing capabilities and the scale and expertise of each company’s respective market, we are creating a vertically integrated organization that serves customers better with readily available nanotech products,” said Yuri Koropachinsky, President of OCSiAl. “Zyvex Technologies has built a tremendous team that we are excited to welcome into the OCSiAl family – and together, we will usher in a new age of technology for businesses and consumers alike.”  

Graphene, a single atom thick sheet of carbon – proclaimed as the ‘wonder material of the 21st century’ by the American Chemical Society – makes batteries more powerful and long-lasting, construction materials lighter, polymers stronger, and improves the electrical and thermal conductivity of composites. In contrast with other technologies, many of its applications do not require changes in currently used equipment or processes. The integration of OCSiAl’s graphene tubes with Zyvex Technologies’ proven operations will allow for the creation of products with properties that significantly surpass what is currently available on the market.

“This is a landmark deal which will open the doors for further development and penetration of nanotechnology through a combination of technology and commercial excellence,” said Dr. Sanjay Mazumdar, CEO of the market research organization, Lucintel. “Businesses must consider the advantages that can be gained through the early adoption of new materials technology, otherwise they’ll watch on the sidelines as their competitors grow.”

Zyvex Technologies will continue to operate with its own distinct brand identity and product line while contributing to the growth of OCSiAl. The combined team will have a presence on six continents and will have 160 dedicated business and R&D staff who have the potential to dramatically change not only the market for carbon nanomaterials but a number of industries, creating new opportunities for carbon enhanced products. Founder and current chairman, Jim Von Ehr, will also join the OCSiAl Board of Directors.

“We are thrilled to join OCSiAl,” said Lance Criscuolo, President of Zyvex Technologies. “Zyvex was the first recognized nanomaterials company in the United States. Now with support from OCSiAl, Zyvex will be in an even better position to bring the potential of nanotechnology into powerful commercial reality.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.